Regulatory T cell mediator proteins and uses thereof
The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T reg -sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed. In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed.
1. A method of inhibiting cytokine expression by CD4 + and/or CD8 + T cells in a subject comprising an inflammatory condition which is not an autoimmune disease comprising the administration of an effective amount of a PD-L3 fusion protein.
2. The method of claim 1 , wherein the PD-L3 fusion protein is a PD-L3-Ig fusion protein.
3. The method of claim 1 , wherein the PD-L3 fusion protein comprises a PD-L3 polypeptide at least 90% identical to SEQ ID NO:4.
4. The method of claim 1 , wherein the cytokines include gamma interferon and IL-2.
5. A method of promoting Treg activity in a subject comprising an inflammatory condition which is not an autoimmune disease comprising the administration of an effective amount of a PD-L3 fusion protein.
6. The method of claim 5 , wherein the PD-L3 fusion protein is a PD-L3-Ig fusion protein.
7. The method of claim 5 , wherein the PD-L3 fusion protein comprises a PD-L3 polypeptide at least 90% identical to SEQ ID NO:4.